Prophylaxis with lactoferrin, a novel antimicrobial agent, in a neonatal rat model of coinfection

Advances in Therapy

Volumn 24, Issue 5, 2007, Pages 941-954

  Venkatesh, Mohan Pammi ^a   Pham, Don ^a   Kong, Lingkun ^a   Weisman, Leonard E ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Candida; Coinfection; Lactoferrin; Neonate; Staphylococcus

Indexed keywords

LACTOFERRIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; FATALITY; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; NEWBORN SEPSIS; NONHUMAN; RAT; STAPHYLOCOCCUS EPIDERMIDIS; WEIGHT GAIN;

ANIMALS; ANIMALS, NEWBORN; ANTI-INFECTIVE AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LACTOFERRIN; MICROBIAL SENSITIVITY TESTS; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; WEIGHT GAIN;

EID: 37249093508     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02877698     Document Type: Article

References (44)

1. Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev. 2004;17:638-680, Table of Contents.
2. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110:285-291.
3. Fanaroff AA, Korones SB, Wright LL, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 1994;330:1107-1113.
4. Faix RG, Kovarik SM. Polymicrobial sepsis among intensive care nursery infants. J Perinatol. 1989;9:131-136.
5. Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA. 2004;292:2357-2365.
6. Venkatesh MP, Pham D, Fein M, et al. Neonatal coinfection model of coagulase-negative staphylococcus (Staphylococcus epidermidis) and Candida albicans: fluconazole prophylaxis enhances survival and growth. Antimicrob Agents Chemother. 2007;51:1240-1245.
7. Hennart PF, Brasseur DJ, Delogne-Desnoeck JB, et al. Lysozyme, lactoferrin, and secretory immunoglobulin A content in breast milk: influence of duration of lactation, nutrition status, prolactin status, and parity of mother. Am J Clin Nutr. 1991;53:32-39.
8. Masson PL, Heremans JF. Lactoferrin in milk from different species. Comp Biochem Physiol B. 1971;39:119-129.
9. Masson P, Heremans J, Dive C. An iron-binding protein common to many external secretions. Clin Chim Acta. 1966;14:735-739.
10. Masson P, Heremans JF, Schonne E. Lactoferrin, an iron-binding protein in neutrophilic leukocytes. J Exp Med. 1969;130:643-658.
11. Bennett RM, Kokocinski T. Lactoferrin content of peripheral blood cells. Br J Haematol. 1978; 39:509-521.
12. Leitch EC, Willcox MD. Lactoferrin increases the susceptibility of S. epidermidis biofilms to lysozyme and vancomycin. Curr Eye Res. 1999;19:12-19.
13. Xu YY, Samaranayake YH, Samaranayake LP, et al. In vitro susceptibility of Candida species to lactoferrin. Med Mycol. 1999;37:35-41.
14. Ward PP, Piddington CS, Cunningham GA, et al. A system for production of commercial quantities of human lactoferrin: a broad spectrum natural antibiotic. Biotechnology (NY). 1995;13:498-503.
15. National Committee on Clinical Laboratory Standards (NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard. 2nd ed. Wayne, Pa: NCCLS; 2002. NCCLS Document M27-A2.
16. Hawser SP, Norris H, Jessup CJ, Ghannoum MA. Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl] -2H-tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J Clin Microbiol. 1998;36:1450-1452.
17. Cerca N, Martins S, Cerca F, et al. Comparative assessment of antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry. J Antimicrob Chemother. 2005;56:331-336.
18. National Committee on Clinical Laboratory Standards (NCCLS). Methods for Dilution in Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard. 6th ed. Wayne, Pa: NCCLS; 2003. NCCLS Document M7-A6.
19. Carlson E, Johnson G. Protection by Candida albicans of Staphylococcus aureus in the establishment of dual infection in mice. Infect Immun. 1985;50:655-659.
20. Carlson E. Effect of strain of Staphylococcus aureus on synergism with Candida albicans resulting in mouse mortality and morbidity. Infect Immun. 1983;42:285-292.
21. Carlson E. Synergistic effect of Candida albicans and Staphylococcus aureus on mouse mortality. Infect Immun. 1982;38:921-924.
22. Adam B, Baillie GS, Douglas LJ. Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. J Med Microbiol. 2002;51:344-349.
23. Ayala A, Chaudry IH. Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Shock. 1996;6(suppl 1):S27-S38.
24. Siddiqui AM, Cui X, Wu R, et al. The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. Crit Care Med. 2006;34:1874-1882.
25. Moreno SE, Alves-Filho JC, Rios-Santos F, et al. Signaling via platelet-activating factor receptors accounts for the impairment of neutrophil migration in polymicrobial sepsis. J Immunol. 2006; 177:1264-1271.
26. Maier S, Emmanuilidis K, Entleutner M, et al. Massive chemokine transcription in acute renal failure due to polymicrobial sepsis. Shock. 2000;14:187-192.
27. Flohe SB, Agrawal H, Schmitz D, et al. Dendritic cells during polymicrobial sepsis rapidly mature but fail to initiate a protective Th1-type immune response. J Leukoc Biol. 2006;79:473-481.
28. Franklin GA, Turina M, Kuhn JF, et al. Organ specific apoptosis following polymicrobial intraperitoneal infection. Inflamm Res. 2006;55:36-143.
29. Ayala A, Chung CS, Xu YX, et al. Increased inducible apoptosis in CD4+ T lymphocytes during polymicrobial sepsis is mediated by Fas ligand and not endotoxin. Immunology. 1999;97:45-55.
30. Farnaud S, Evans RW. Lactoferrin - a multifunctional protein with antimicrobial properties. Mol Immunol. 2003;40:395-405.
31. Orsi N. The antimicrobial activity of lactoferrin: current status and perspectives. Biometals. 2004; 17:189-196.
32. Legrand D, Elass E, Pierce A, et al. Lactoferrin and host defense: an overview of its immunomodulating and anti-inflammatory properties. Biometals. 2004;17:225-229.
33. Kruzel ML, Harari Y, Mailman D, et al. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin Exp Immunol. 2002;130:25-31.
34. Leitch EC, Willcox MD. Elucidation of the antistaphylococcal action of lactoferrin and lysozyme. J Med Microbiol. 1999;48:867-871.
35. Wakabayashi H, Abe S, Okutomi T, et al. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol Immunol. 1996;40:821-825.
36. Wakabayashi H, Okutomi T, Abe S, et al. Enhanced anti-Candida activity of neutrophils and azole antifungal agents in the presence of lactoferrin-related compounds. Adv Exp Med Biol. 1998;443:229-237.
37. Peen E, Johansson A, Engquist M, et al. Hepatic and extrahepatic clearance of circulating human lactoferrin: an experimental study in rat. Eur J Haematol. 1998;61:151-159.
38. Wakabayashi H, Kuwata H, Yamauchi K, et al. No detectable transfer of dietary lactoferrin or its functional fragments to portal blood in healthy adult rats. Biosci Biotechnol Biochem. 2004; 68:853-860.
39. Harris MC, D'Angio CT, Gallagher PR, et al. Cytokine elaboration in critically ill infants with bacterial sepsis, necrotizing entercolitis, or sepsis syndrome: correlation with clinical parameters of inflammation and mortality. J Pediatr. 2005;147:462-468.
40. Shapiro N, Howell MD, Bates DW, et al. The association of sepsis syndrome and organ dysfunction with mortality in emergency department patients with suspected infection. Ann Emerg Med. 2006;48:583-590.
41. Sprung CL, Sakr Y, Vincent JL, et al. An evaluation of systemic inflammatory response syndrome signs in the Sepsis Occurrence in Acutely ill Patients (SOAP) study. Intensive Care Med. 2006;32:421-427.
42. Edde L, Hipolito RB, Hwang FF, et al. Lactoferrin protects neonatal rats from gut-related systemic infection. Am J Physiol Castrointest Liver Physiol. 2001;281:G1140-G1150.
43. Gomez HF, Ochoa TJ, Herrera-Insua I, et al. Lactoferrin protects rabbits from Shigella flexneriinduced inflammatory enteritis. Infect Immun. 2002;70:7050-7053.
44. Tran TV, Weisman LE. Dexamethasone effects on group B streptococcal infection in newborn rats. Pediatr Infect Dis J. 2004;23:47-52.